Show simple item record

AuthorFojnica, Adnan
AuthorLjuca, Kenana
AuthorAkhtar, Saghir
AuthorGatalica, Zoran
AuthorVranic, Semir
Available date2024-01-16T08:10:46Z
Publication Date2023-10-01
Publication NameCancers
Identifierhttp://dx.doi.org/10.3390/cancers15205084
CitationFojnica, A., Ljuca, K., Akhtar, S., Gatalica, Z., & Vranic, S. (2023). An Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy. Cancers, 15(20), 5084.‏
URIhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85175066800&origin=inward
URIhttp://hdl.handle.net/10576/50761
AbstractMerkel cell carcinoma (MCC) is primarily a disease of the elderly Caucasian, with most cases occurring in individuals over 50. Immune checkpoint inhibitors (ICI) treatment has shown promising results in MCC patients. Although ~34% of MCC patients are expected to exhibit at least one of the predictive biomarkers (PD-L1, high tumor mutational burden/TMB-H/, and microsatellite instability), their clinical significance in MCC is not fully understood. PD-L1 expression has been variably described in MCC, but its predictive value has not been established yet. Our literature survey indicates conflicting results regarding the predictive value of TMB in ICI therapy for MCC. Avelumab therapy has shown promising results in Merkel cell polyomavirus (MCPyV)-negative MCC patients with TMB-H, while pembrolizumab therapy has shown better response in patients with low TMB. A study evaluating neoadjuvant nivolumab therapy found no significant difference in treatment response between the tumor etiologies and TMB levels. In addition to ICI therapy, other treatments that induce apoptosis, such as milademetan, have demonstrated positive responses in MCPyV-positive MCC, with few somatic mutations and wild-type TP53. This review summarizes current knowledge and discusses emerging and potentially predictive biomarkers for MCC therapy with ICI.
Languageen
PublisherMultidisciplinary Digital Publishing Institute (MDPI)
Subjectbiomarkers
immune checkpoint inhibitors
Merkel cell carcinoma
skin
therapy
TitleAn Updated Review of the Biomarkers of Response to Immune Checkpoint Inhibitors in Merkel Cell Carcinoma: Merkel Cell Carcinoma and Immunotherapy
TypeArticle
Pagination5084
Issue Number20
Volume Number15
dc.accessType Open Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record